Last update March 25, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
モサプリドクエン酸塩 is Mosapride Citrate in Japanese.Is written in other languages:
モサプリドクエン酸塩 is also known as
モサプリドクエン酸塩 belongs to this group or family:
Main tradenames from several countries containing モサプリドクエン酸塩 in its composition:
|Tmax||0.8 ± 0.1||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Mosapride, a substituted benzamide, is a prokinetic drug that increases gastrointestinal motility and accelerates gastric emptying. Used in gastritis and gastroesophageal reflux. Oral administration.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (very high percentage of protein binding and moderately high molecular weight) make it highly unlikely that significant quantities will pass into breast milk.
No cardiac arrhythmias have been reported in patients treated with mosaprida, unlike what happens with a similar drug, cisapride. (Tack 2012, Cho 2004, Endo 2002)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
See below the information of this related product: